Enanta Pharmaceuticals (ENTA) Free Cash Flow Growth (5y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.78% |
| Dec 31, 2025 | 4.72% |
| Sep 30, 2025 | -3.22% |
| Jun 30, 2025 | 51.02% |
| Mar 31, 2025 | -25.11% |
| Dec 31, 2024 | -32.93% |
| Sep 30, 2024 | -36.04% |
| Jun 30, 2024 | -129.62% |
| Mar 31, 2024 | -25.08% |
| Dec 31, 2023 | -23.65% |
| Sep 30, 2023 | -22.97% |
| Jun 30, 2023 | -53.59% |
| Mar 31, 2023 | -13.13% |
| Dec 31, 2022 | -61.62% |
| Sep 30, 2022 | -17.93% |
| Jun 30, 2022 | -40.07% |
| Mar 31, 2022 | -49.53% |
| Dec 31, 2021 | -51.86% |
| Sep 30, 2021 | -73.99% |
| Jun 30, 2021 | -60.70% |
| Mar 31, 2021 | -20.60% |
| Dec 31, 2020 | -20.52% |
| Sep 30, 2020 | -31.16% |
| Jun 30, 2020 | 20.36% |
| Mar 31, 2020 | -31.36% |
| Dec 31, 2019 | 32.11% |
| Sep 30, 2019 | 28.64% |
| Jun 30, 2019 | -61.26% |
| Mar 31, 2019 | 54.04% |
| Dec 31, 2018 | 47.20% |
| Sep 30, 2018 | 65.62% |
| Jun 30, 2018 | 23.53% |
| Mar 31, 2018 | -23.73% |
| Dec 31, 2017 | -13.81% |
| Sep 30, 2017 | 101.82% |
| Jun 30, 2017 | -7.40% |